Dexanabinol HU211

The cannabinoid analog dexanabinol, which demonstrated protective efficacy in preclinical TBI models,28 has been tested in a phase II clinical trial in severe TBI patients. The new compound entity was found to be safe and showed that patients treated within 6 h tended to have better control of intracranial and cerebral perfusion pressures.29 This new compound entity is unique in that it combines antioxidant and weak NMDA receptor antagonist properties along with selected anti-inflammatory properties. However, a recently completed multicenter, multinational, phase III trial has reportedly failed to show neuroprotective efficacy.

Back Pain Relief

Back Pain Relief

This informational eBook will present you with the most recent research and findings available so that you can learn more about Back Pain relief, covering as many bases as possible from A to Z.

Get My Free Ebook


Post a comment